News
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four ...
Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback